InMed Pharmaceuticals (INM) Other Non-Current Assets (2020 - 2026)

InMed Pharmaceuticals has reported Other Non-Current Assets for 7 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 970.31% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 970.31% YoY), and the FY2025 full-year result was $1.8 million, up 1660.92% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.1 million, up from $100000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.8 million in Q2 2025, with the low at $100000.0 in Q4 2023.
• Historically, Other Non-Current Assets has averaged $271349.4 across 5 years, with a median of $101790.0 in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 1884.12% — and 2023, when it plunged 41.56%.
• InMed Pharmaceuticals' Other Non-Current Assets stood at $171130.0 in 2022, then sank by 41.56% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then surged by 970.31% to $1.1 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.1 million (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.